Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observation Study on the Efficacy and Safety of Hepatic Artery Embolization Combined With Radiofrequency Ablation for Hepatic Hemangioma: The Impact of Different Treatment Intervals

NCT07919860 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT07919860 Not yet recruiting Observational 80 participants (estimated) Started 2027

Follow this trial by email Email me the PDF

Get the NCT07919860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Not yet recruiting, started January 2027. Observational study, 80 participants (estimated). Lead sponsor Beijing Tiantan Hospital. Primary measure: Tumour volume reduction rate.

Registry record

As filed in ClinicalTrials.gov.

Title
Observation Study on the Efficacy and Safety of Hepatic Artery Embolization Combined With Radiofrequency Ablation for Hepatic Hemangioma: The Impact of Different Treatment Intervals
Lead sponsor
Beijing Tiantan Hospital
Phase
Observational
Overall status
Not yet recruiting
Start date
January 1, 2027
Completion date
December 31, 2029
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them.

hepatic hemangioma

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
80 Years
Healthy volunteers
No
Study type
Observational
Lead sponsor
Beijing Tiantan Hospital

Arms

As registered; 2 arms.

Registered arms
Arm Type Interventions
Short-interval group radiofrequency ablation (RFA), transcatheter arterial embolization (TAE)
Show registry wording

RFA is performed at 10-14 days after TAE

Long-interval group radiofrequency ablation (RFA), transcatheter arterial embolization (TAE)
Show registry wording

RFA is performed at 2-3 months after TAE

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Tumour volume reduction rate 6 month and 12 month post RFA

Lead sponsor's other trials

Beijing Tiantan Hospital, most recent start first.